APA (7th ed.) Citation

Lynce, F., Wang, H., Petricoin, E. F., Pohlmann, P. R., Smaglo, B., Hwang, J., . . . Pishvaian, M. J. (2019). A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies. Cancer Chemotherapy & Pharmacology, 84(5), 1145. https://doi.org/10.1007/s00280-019-03947-7

Chicago Style (17th ed.) Citation

Lynce, Filipa, et al. "A Phase I Study of HER1, HER2 Dual Kinase Inhibitor Lapatinib Plus the Proteasome Inhibitor Bortezomib in Patients with Advanced Malignancies." Cancer Chemotherapy & Pharmacology 84, no. 5 (2019): 1145. https://doi.org/10.1007/s00280-019-03947-7.

MLA (9th ed.) Citation

Lynce, Filipa, et al. "A Phase I Study of HER1, HER2 Dual Kinase Inhibitor Lapatinib Plus the Proteasome Inhibitor Bortezomib in Patients with Advanced Malignancies." Cancer Chemotherapy & Pharmacology, vol. 84, no. 5, 2019, p. 1145, https://doi.org/10.1007/s00280-019-03947-7.